West Pharmaceutical Services Toekomstige groei
Future criteriumcontroles 1/6
West Pharmaceutical Services zal naar verwachting groeien in winst en omzet met respectievelijk 12.7% en 6.9% per jaar. De winst per aandeel zal naar verwachting groeien met 12% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 16.3% zijn.
Belangrijke informatie
12.7%
Groei van de winst
12.0%
Groei van de winst per aandeel
| Life Sciences winstgroei | 18.4% |
| Inkomstengroei | 6.9% |
| Toekomstig rendement op eigen vermogen | 16.3% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 29 Oct 2024 |
Recente toekomstige groei-updates
West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27
West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28Recent updates
Should You Think About Buying West Pharmaceutical Services, Inc. (NYSE:WST) Now?
Nov 15West Pharmaceutical Services, Inc. Just Recorded A 27% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 27West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Oct 11Getting In Cheap On West Pharmaceutical Services, Inc. (NYSE:WST) Is Unlikely
Sep 20A Look At The Intrinsic Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Sep 02West Pharmaceutical Services, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 28West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
Jul 25Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
Jul 15We Think West Pharmaceutical Services (NYSE:WST) Can Stay On Top Of Its Debt
Jun 27Estimating The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
May 21West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
May 11West Pharmaceutical Services, Inc.'s (NYSE:WST) Business Is Yet to Catch Up With Its Share Price
Mar 30Is West Pharmaceutical Services (NYSE:WST) A Risky Investment?
Mar 12Why West Pharma Is Far From Done
Feb 28West Pharmaceutical Services, Inc.'s (NYSE:WST) Intrinsic Value Is Potentially 19% Below Its Share Price
Feb 20West Pharmaceutical Services: Still Too Expensive After The Recent Drop
Feb 20What Does West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Indicate?
Jan 10West Pharmaceutical: Great Business, Not So Great Valuation
Jan 08What West Pharmaceutical Services, Inc.'s (NYSE:WST) P/E Is Not Telling You
Dec 18West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Nov 27West Pharmaceutical Services: The Run Might Be Over
Oct 18Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
Sep 24Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
Aug 22West Pharmaceutical: Revise To Buy On Exceptional Economic Characteristics
Aug 08What Is West Pharmaceutical Services, Inc.'s (NYSE:WST) Share Price Doing?
Jun 26West Pharmaceutical: Hard To Justify The Price
May 26Is West Pharmaceutical Services (NYSE:WST) Using Too Much Debt?
May 16At US$330, Is It Time To Put West Pharmaceutical Services, Inc. (NYSE:WST) On Your Watch List?
Mar 20West Pharmaceutical Services' (NYSE:WST) Soft Earnings Don't Show The Whole Picture
Feb 28West Pharmaceutical Q4 2022 Earnings Preview
Feb 15West Pharmaceutical Services (NYSE:WST) Has A Pretty Healthy Balance Sheet
Jan 31West Pharmaceutical: An Earnings Decline Seen In 2023, Shares Still Appear Expensive
Dec 19West Pharmaceutical declares $0.19 dividend
Dec 13Why West Pharmaceutical Services, Inc. (NYSE:WST) Could Be Worth Watching
Nov 29Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 3,339 | 656 | 553 | 860 | 8 |
| 12/31/2025 | 3,066 | 556 | 451 | 743 | 10 |
| 12/31/2024 | 2,883 | 479 | 244 | 634 | 10 |
| 9/30/2024 | 2,876 | 500 | 322 | 702 | N/A |
| 6/30/2024 | 2,877 | 525 | 357 | 752 | N/A |
| 3/31/2024 | 2,929 | 569 | 386 | 757 | N/A |
| 12/31/2023 | 2,950 | 593 | 415 | 777 | N/A |
| 9/30/2023 | 2,927 | 559 | 420 | 768 | N/A |
| 6/30/2023 | 2,866 | 519 | 397 | 707 | N/A |
| 3/31/2023 | 2,884 | 552 | 410 | 711 | N/A |
| 12/31/2022 | 2,887 | 586 | 439 | 724 | N/A |
| 9/30/2022 | 2,909 | 631 | 388 | 654 | N/A |
| 6/30/2022 | 2,929 | 686 | 402 | 675 | N/A |
| 3/31/2022 | 2,881 | 684 | 382 | 647 | N/A |
| 12/31/2021 | 2,832 | 662 | 331 | 584 | N/A |
| 9/30/2021 | 2,681 | 613 | 341 | 572 | N/A |
| 6/30/2021 | 2,523 | 519 | 287 | 500 | N/A |
| 3/31/2021 | 2,326 | 423 | 307 | 504 | N/A |
| 12/31/2020 | 2,147 | 346 | 298 | 473 | N/A |
| 9/30/2020 | 2,037 | 312 | 272 | 430 | N/A |
| 6/30/2020 | 1,945 | 286 | 277 | 420 | N/A |
| 3/31/2020 | 1,888 | 261 | 247 | 377 | N/A |
| 12/31/2019 | 1,840 | 242 | 241 | 367 | N/A |
| 9/30/2019 | 1,792 | 230 | 215 | 334 | N/A |
| 6/30/2019 | 1,767 | 229 | 201 | 314 | N/A |
| 3/31/2019 | 1,745 | 219 | 186 | 291 | N/A |
| 12/31/2018 | 1,717 | 207 | 184 | 289 | N/A |
| 9/30/2018 | 1,711 | 155 | 193 | 297 | N/A |
| 6/30/2018 | 1,677 | 151 | N/A | 284 | N/A |
| 3/31/2018 | 1,627 | 133 | N/A | 288 | N/A |
| 12/31/2017 | 1,599 | 151 | N/A | 263 | N/A |
| 9/30/2017 | 1,566 | 190 | N/A | 254 | N/A |
| 6/30/2017 | 1,544 | 176 | N/A | 246 | N/A |
| 3/31/2017 | 1,535 | 182 | N/A | 237 | N/A |
| 12/31/2016 | 1,509 | 144 | N/A | 219 | N/A |
| 9/30/2016 | 1,487 | 138 | N/A | 216 | N/A |
| 6/30/2016 | 1,454 | 102 | N/A | 216 | N/A |
| 3/31/2016 | 1,426 | 85 | N/A | 217 | N/A |
| 12/31/2015 | 1,400 | 96 | N/A | 212 | N/A |
| 9/30/2015 | 1,390 | 94 | N/A | 190 | N/A |
| 6/30/2015 | 1,401 | 123 | N/A | 186 | N/A |
| 3/31/2015 | 1,411 | 133 | N/A | 172 | N/A |
| 12/31/2014 | 1,421 | 127 | N/A | 183 | N/A |
| 9/30/2014 | 1,414 | 119 | N/A | 206 | N/A |
| 6/30/2014 | 1,400 | 115 | N/A | 195 | N/A |
| 3/31/2014 | 1,376 | 108 | N/A | 210 | N/A |
| 12/31/2013 | 1,368 | 112 | N/A | 221 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei WST ( 12.7% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van WST ( 12.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).
Hoge groeiwinsten: De winst van WST zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van WST ( 6.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van WST ( 6.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen WST zal naar verwachting over 3 jaar laag zijn ( 16.3 %).